<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li J</submitter><funding>National Natural Science Foundation of China</funding><pagination>e1878</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8922959</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(3)</volume><pubmed_abstract>Hereditary multiple exostosis (HME) is an autosomal dominant skeletal disorder characterized by the development of multiple cartilage-covered tumors on the external surfaces of bones (osteochondromas). Most of HME cases result from heterozygous loss-of-function mutations in EXT1 or EXT2 gene. Clinical examination was performed to diagnose the patients: Whole exome sequencing (WES) was used to identify pathogenic mutations in the proband, which is confirmed by Sanger sequencing and co-segregation analysis: qRT-PCR was performed to identify the mRNA expression level of EXT1 in patient peripheral blood samples: minigene splicing assay was performed to mimic the splicing process of EXT1 variants in vitro. We evaluated the pathogenicity of EXT1 c.1056 + 1G > T in a Chinese family with HME. The </pubmed_abstract><journal>Molecular genetics &amp; genomic medicine</journal><pubmed_title>Genetic and functional analyses detect an EXT1 splicing pathogenic variant in a Chinese hereditary multiple exostosis (HME) family.</pubmed_title><pmcid>PMC8922959</pmcid><funding_grant_id>82172011</funding_grant_id><pubmed_authors>Cheng D</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Jin C</pubmed_authors><pubmed_authors>Han Y</pubmed_authors><pubmed_authors>Zhen J</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Zhou YA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Genetic and functional analyses detect an EXT1 splicing pathogenic variant in a Chinese hereditary multiple exostosis (HME) family.</name><description>Hereditary multiple exostosis (HME) is an autosomal dominant skeletal disorder characterized by the development of multiple cartilage-covered tumors on the external surfaces of bones (osteochondromas). Most of HME cases result from heterozygous loss-of-function mutations in EXT1 or EXT2 gene. Clinical examination was performed to diagnose the patients: Whole exome sequencing (WES) was used to identify pathogenic mutations in the proband, which is confirmed by Sanger sequencing and co-segregation analysis: qRT-PCR was performed to identify the mRNA expression level of EXT1 in patient peripheral blood samples: minigene splicing assay was performed to mimic the splicing process of EXT1 variants in vitro. We evaluated the pathogenicity of EXT1 c.1056 + 1G > T in a Chinese family with HME. The </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-04T08:01:29.86Z</modification><creation>2025-04-04T08:01:29.86Z</creation></dates><accession>S-EPMC8922959</accession><cross_references><pubmed>35106951</pubmed><doi>10.1002/mgg3.1878</doi></cross_references></HashMap>